Atopic Dermatitis Clinical Trials Market Report 2026

Atopic Dermatitis Clinical Trials Market Overview

• Atopic Dermatitis Clinical Trials market size has reached to $2.74 billion in 2025 • Expected to grow to $4.78 billion in 2030 at a compound annual growth rate (CAGR) of 11.7% • Growth Driver: Surge In Pharmaceutical And Biopharma Investments Fueling The Growth Of The Market Due To Rising Demand For Innovative Therapies • Market Trend: Strategic Food And Drug Administration Approvals Support Broader Access To Innovative Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Atopic Dermatitis Clinical Trials Market?

Atopic dermatitis clinical trials refer to research studies conducted to evaluate the safety, efficacy, and tolerability of new or existing therapies, including drugs, biologics, and topical agents, for treating atopic dermatitis, a chronic inflammatory skin condition. These trials play a crucial role in advancing treatment options by assessing outcomes such as symptom reduction, flare-up frequency, and quality of life improvements in affected patients. The main phases of atopic dermatitis clinical trials include phase I, phase II, phase III, and phase IV. Phase I trials are the first tests of a new treatment in humans, typically involving a small group (around 20–80 participants). It is used for both small and large molecules and offers various study designs, including interventional and observational. It can be delivered through various modes, such as outsourced and in-house, and is used by several industries, including contract research organizations, pharmaceutical and biotechnology companies, and research and academic institutes.

What Is The Atopic Dermatitis Clinical Trials Market Growth Forecast?

The atopic dermatitis clinical trials market size is expected to see rapid growth in the next few years. It will grow to $4.78 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to growing demand for novel biologics and JAK inhibitors, rising adoption of decentralized clinical trials, increasing use of real-world evidence studies, expansion of personalized treatment approaches, increasing regulatory approvals for advanced therapies. Major trends in the forecast period include increasing adoption of biologic and targeted therapies in trials, rising use of digital patient monitoring tools, growing emphasis on patient-centric trial designs, expansion of late-phase multicenter studies, enhanced focus on long-term safety and quality of life endpoints.

Global Atopic Dermatitis Clinical Trials Market Segmentation

1) By Phase: Phase I, Phase II, Phase III, Phase IV 2) By Molecule Type: Small Molecules, Large Molecules 3) By Study Designs: Interventional, Observational 4) By Mode: Outsourced, In-House 5) By Industry: Contract Research Organizations, Pharmaceutical And Biotechnology Companies, Research And Academic Institutes Subsegments: 1) By Phase I: Safety And tolerability studies, Dose-Escalation studies, Pharmacokinetics (PK) And Pharmacodynamics (PD) Studies 2) By Phase II: Dose-Ranging Studies, Efficacy And Safety Studies, Randomized Controlled Trials (RCTs), Biomarker Identification Studies 3) By Phase III: Large-Scale Efficacy Studies, Comparative Effectiveness Trials, Multicenter Randomized Trials, Long-Term Safety Assessment 4) By Phase IV: Post-Marketing Surveillance, Real-World Evidence Studies, Drug Utilization Studies, Health Outcomes And Quality Of Life Studies

What Is The Driver Of The Atopic Dermatitis Clinical Trials Market?

The increasing pharmaceutical and biopharma investments are expected to propel the growth of the atopic dermatitis clinical trials market going forward. Pharmaceutical and biopharma investments refer to funding and capital allocation toward the research, development, manufacturing, and commercialization of drugs and biologic therapies. The rise in pharmaceutical and biopharma investments is due to the increasing demand for innovative therapies, as they offer targeted treatment options and improved patient outcomes. Pharmaceutical and biopharma investments support atopic dermatitis clinical trials by funding the research and testing of new treatments, allowing scientists to carry out comprehensive studies that confirm their effectiveness and safety. For instance, in December 2024, according to the Association of Australian Medical Research Institutes (AAMRI), an Australia-based nonprofit organization, in 2023, Australian medical-research institutes collectively received approximately AUD 2.5 billion (~ USD 1.65 billion) in total revenue. Therefore, the increasing pharmaceutical and biopharma investments are driving the growth of the atopic dermatitis clinical trials industry.

Key Players In The Global Atopic Dermatitis Clinical Trials Market

Major companies operating in the atopic dermatitis clinical trials market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis International AG, Sanofi S.A., GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Organon & Co., Charles River Laboratories International Inc., LEO Pharma A/S, QIMA Limited, Medpace Holdings Inc., Novotech Health Holdings Pte Ltd., Biocytogen Pharmaceuticals Co. Ltd., REPROCELL Inc., AnaptysBio Inc., Imavita S.A.S., Oncodesign Services S.A.S.

Global Atopic Dermatitis Clinical Trials Market Trends and Insights

Major companies operating in the atopic dermatitis clinical trials market are focusing on developing innovative products, such as oral inhibitors, to maintain stable therapeutic effects over time. Oral inhibitors are drugs administered by mouth that work by blocking certain enzymes or signaling pathways involved in disease progression. For instance, in February 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology company, announced that the US Food and Drug Administration approved its supplemental New Drug Application for CIBINQO (abrocitinib). This approval expanded the drug’s use to adolescents aged 12 to under 18 with moderate-to-severe atopic dermatitis not controlled by other systemic treatments or biologics. Previously, CIBINQO was approved only for adults 18 and older. This expansion provides a new treatment option for younger patients with difficult-to-treat AD. The decision is based on clinical trial evidence demonstrating its safety and effectiveness in this age group.

What Are Latest Mergers And Acquisitions In The Atopic Dermatitis Clinical Trials Market?

In May 2024, Johnson & Johnson Services Inc., a US-based multinational pharmaceutical and consumer health company, acquired Yellow Jersey Therapeutics AG for approximately US$ 1.25 billion. With this acquisition, Johnson & Johnson Services, Inc. aims to secure global development, manufacturing, and commercialization rights to a novel bispecific antibody, strengthening its immunology and dermatology drug pipeline and accelerating its entry into next-generation treatments for skin diseases. Yellow Jersey Therapeutics AG is a Switzerland-based biotech subsidiary that holds the investigational bispecific antibody NM26, a first-in-class therapy targeting IL-4Rα and IL-31, designed to treat atopic dermatitis and related conditions.

Regional Outlook

North America was the largest region in the atopic dermatitis clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Atopic Dermatitis Clinical Trials Market?

The atopic dermatitis clinical trials market consists of revenues earned by entities by providing services such as preclinical and translational research services, decentralized and virtual trial services, and patient engagement and retention programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The atopic dermatitis clinical trials market also includes sales of topical corticosteroids, oral immunosuppressants, barrier repair creams, and antihistamines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Atopic Dermatitis Clinical Trials Market Report 2026?

The atopic dermatitis clinical trials market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the atopic dermatitis clinical trials industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.